Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 195,600 shares, a decline of 14.2% from the August 31st total of 228,000 shares. Based on an average trading volume of 162,200 shares, the short-interest ratio is presently 1.2 days. Approximately 0.8% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. acquired a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned 0.09% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock traded up $0.04 during trading on Friday, reaching $0.62. The company’s stock had a trading volume of 244,673 shares, compared to its average volume of 175,730. The company has a 50-day moving average price of $0.68 and a two-hundred day moving average price of $0.87. Bolt Biotherapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.56. The firm has a market cap of $23.65 million, a PE ratio of -0.37 and a beta of 0.93. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.19.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, August 13th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.08). Bolt Biotherapeutics had a negative net margin of 592.57% and a negative return on equity of 61.40%. The business had revenue of $1.28 million during the quarter, compared to analysts’ expectations of $1.19 million. On average, analysts forecast that Bolt Biotherapeutics will post -1.44 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday, August 15th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.